Pancreatic Cancer Research

ResearcherStony Brook UniversityActive in the last 2 years

Richard A. Moffitt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2723-5902; OpenAlex author ID A5022550153. Sources: OpenAlex.

Their work

Papers
21 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
78
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: 3 papers · 2019: 2 papers · 2020: 4 papers · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 21

  1. Correction: Differential Control of Growth and Identity by HNF4α Isoforms in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-25-1225↗
  2. MetScore and classical–basal subtype intersect to define chemotherapy response and tumor microenvironment architecture in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.09.14.751470↗
  3. Differential Control of Growth and Identity by HNF4α Isoforms in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-25-0175↗
  4. Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy. Co-author DOI 10.1136/jitc-2023-008086↗
  5. Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtype. Last author DOI 10.1038/s41467-023-40895-6↗
  6. Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-subtype model. Last author DOI 10.1038/s42003-023-04461-6↗
  7. Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. Co-author DOI 10.1038/s41467-021-23237-2↗
  8. Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4. Co-author DOI 10.1136/gutjnl-2020-321316↗
  9. Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.08.015↗
  10. Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. Co-author DOI 10.1038/s41416-020-0879-6↗
  11. Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1467↗
  12. Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. Co-author DOI 10.1172/jci.insight.129905↗
  13. Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0298-0↗
  14. Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer. Co-author DOI 10.1038/s41598-019-47519-4↗
  15. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Co-author DOI 10.1158/1078-0432.ccr-17-2994↗
  16. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Co-author DOI 10.1158/2159-8290.cd-18-0275↗
  17. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
  18. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2017.07.007↗
  19. Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer. Co-author DOI 10.18632/oncotarget.9760↗
  20. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ng.3398↗
  21. Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma. Co-author DOI 10.1371/journal.pone.0089474↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eric Lee Snyder · 3 shared papers, 2021–2026 · strength 0.64
  2. Jen Jen Yeh · 7 shared papers, 2014–2023 · strength 0.61
  3. Kajsa E. Affolter · 2 shared papers, 2025–2026 · strength 0.52
  4. Pengshu Fang · 2 shared papers, 2025–2026 · strength 0.52
  5. Walter Alexander Orellana · 2 shared papers, 2025–2026 · strength 0.52
  6. Gregory B. Lesinski · 2 shared papers, 2024–2026 · strength 0.49
  7. Luke A. Torre-Healy · 3 shared papers, 2021–2023 · strength 0.47
  8. Naim U. Rashid · 4 shared papers, 2015–2023 · strength 0.41
  9. Ki Oh · 2 shared papers, 2023 · strength 0.35
  10. Mei Gao · 3 shared papers, 2019–2023 · strength 0.34
  11. Joseph Kim · 3 shared papers, 2019–2023 · strength 0.34
  12. Jesse Stone Handler · 1 shared paper, 2026 · strength 0.29
  13. Udhayvir Singh Grewal · 1 shared paper, 2026 · strength 0.29
  14. Kawther Abdilleh · 1 shared paper, 2026 · strength 0.29
  15. Raymond E. Preston · 1 shared paper, 2026 · strength 0.29
  16. Olatunji Boladale Alese · 1 shared paper, 2026 · strength 0.29
  17. Sudheer Doss Doss · 1 shared paper, 2026 · strength 0.29
  18. Kenneth Reed Shroyer · 3 shared papers, 2019–2020 · strength 0.28
  19. Ryan R. Kawalerski · 2 shared papers, 2020–2023 · strength 0.27
  20. Chrystal M Paulos · 1 shared paper, 2024 · strength 0.20
  21. Cameron J. Herting · 1 shared paper, 2024 · strength 0.20
  22. Natalie K. Horvat · 1 shared paper, 2024 · strength 0.20
  23. Andrew J. Aguirre · 1 shared paper, 2023 · strength 0.18
  24. Jeffrey L. Vacirca · 2 shared papers, 2019–2020 · strength 0.18
  25. Marcela d'Alincourt Salazar · 2 shared papers, 2019–2020 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.